Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications.
作者信息
Zanghì Aurora, Avolio Carlo, Hartung Hans-Peter, D'Amico Emanuele
机构信息
Unitá Operativa Complessa (UOC) Neurology, Sant'Elia Hospital, Caltanissetta, Italy.
Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
出版信息
Front Neurol. 2022 Aug 30;13:996342. doi: 10.3389/fneur.2022.996342. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications.社论：免疫衰老与多发性硬化症：预后及治疗意义
Front Neurol. 2022 Aug 30;13:996342. doi: 10.3389/fneur.2022.996342. eCollection 2022.
2
Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration.免疫衰老与多发性硬化症：炎症衰老对预后及治疗的考量
Front Aging. 2023 Oct 13;4:1234572. doi: 10.3389/fragi.2023.1234572. eCollection 2023.
3
Understanding the Complex Dynamics of Immunosenescence in Multiple Sclerosis: From Pathogenesis to Treatment.了解多发性硬化症中免疫衰老的复杂动态：从发病机制到治疗。
Biomedicines. 2024 Aug 19;12(8):1890. doi: 10.3390/biomedicines12081890.
4
Molecular Mechanisms of Immunosenescene and Inflammaging: Relevance to the Immunopathogenesis and Treatment of Multiple Sclerosis.免疫衰老和炎症衰老的分子机制：与多发性硬化症的免疫发病机制及治疗的相关性
Front Neurol. 2022 Feb 25;12:811518. doi: 10.3389/fneur.2021.811518. eCollection 2021.
5
Inflammaging, immunosenescence, and cardiovascular aging: insights into long COVID implications.炎症衰老、免疫衰老与心血管衰老：对新冠长期影响的见解
Front Cardiovasc Med. 2024 Jun 26;11:1384996. doi: 10.3389/fcvm.2024.1384996. eCollection 2024.
6
The emerging roles and therapeutic implications of immunosenescence-mediated inflammaging in age-related hearing loss.免疫衰老介导的炎症衰老在年龄相关性听力损失中的新作用及治疗意义
Am J Stem Cells. 2024 Apr 25;13(2):101-109. doi: 10.62347/DTAP3592. eCollection 2024.
7
Immunosenescence, inflammaging, and cancer immunotherapy efficacy.免疫衰老、炎症衰老与癌症免疫治疗疗效。
Expert Rev Anticancer Ther. 2022 Sep;22(9):915-926. doi: 10.1080/14737140.2022.2098718. Epub 2022 Jul 14.
8
Immunosenescence in multiple sclerosis: the identification of new therapeutic targets.多发性硬化症中的免疫衰老：新治疗靶点的鉴定。
Autoimmun Rev. 2021 Sep;20(9):102893. doi: 10.1016/j.autrev.2021.102893. Epub 2021 Jul 5.
9
Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis.多发性硬化症早期免疫衰老过程中 CSF 中出现的免疫变化的鉴定。
Front Immunol. 2021 Jul 12;12:685139. doi: 10.3389/fimmu.2021.685139. eCollection 2021.
10
Should we Try to Alleviate Immunosenescence and Inflammaging - Why, How and to What Extent?我们是否应该努力缓解免疫衰老和炎症衰老——为什么、如何以及在多大程度上？
Curr Pharm Des. 2019;25(39):4154-4162. doi: 10.2174/1381612825666191111153016.
本文引用的文献
1
Immunosenescence: the role of age in multiple sclerosis.免疫衰老：多发性硬化症中的年龄作用。
Neurologia (Engl Ed). 2023 May;38(4):284-290. doi: 10.1016/j.nrleng.2020.05.023. Epub 2022 Mar 5.
2
First-line therapies in late-onset multiple sclerosis: An Italian registry study.晚发性多发性硬化症的一线治疗：一项意大利登记研究。
Eur J Neurol. 2021 Dec;28(12):4117-4123. doi: 10.1111/ene.15006. Epub 2021 Jul 30.
3
Exploring polypharmacy phenomenon in newly diagnosed relapsing-remitting multiple sclerosis: a cohort ambispective single-centre study.探索新诊断复发缓解型多发性硬化症中的多重用药现象：一项队列双瞻性单中心研究。
Ther Adv Chronic Dis. 2021 Feb 27;12:2040622320983121. doi: 10.1177/2040622320983121. eCollection 2021.
4
Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials.衰老与多发性硬化症疾病修正疗法的疗效：一项临床试验的荟萃分析
Ther Adv Neurol Disord. 2020 Oct 28;13:1756286420969016. doi: 10.1177/1756286420969016. eCollection 2020.
5
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.迟发性和早发性复发缓解型多发性硬化症：来自回顾性长期随访研究的证据。
Eur J Neurol. 2018 Dec;25(12):1425-1431. doi: 10.1111/ene.13745. Epub 2018 Aug 3.
6
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives.进展性多发性硬化症的个性化治疗方法：疾病修正疗法（DMTs）的现状与未来展望
Int J Mol Sci. 2016 Oct 17;17(10):1725. doi: 10.3390/ijms17101725.
7
Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis.
Neurol Sci. 2004 Nov;25 Suppl 4:S350-5. doi: 10.1007/s10072-004-0339-8.
Zotero 插件